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Objective: To investigate differences in postoperative outcomes between short-course radiotherapy and
delayed surgery (SCRT-delay) and chemoradiation (CRT) in patients with locally advanced rectal cancer
(LARC).
Background: Previous trials suggest that SCRT-delay could serve as an adequate neoadjuvant treatment
for LARC. Therefore, in frail LARC patients SCRT-delay is recommended as an alternative to CRT. However,
data on postoperative outcomes after SCRT-delay in comparison to CRT is scarce.
Methods: This was an observational study with data from the Dutch ColoRectal Audit (DCRA). LARC
patients who underwent surgery (2014e2017) after an interval of 6 weeks were included. Missing
values were replaced by multiple imputation. Propensity score matching (PSM), using age, Charlson
Comorbidity Index, cT-stage and surgical procedure, was applied to create comparable groups. Differ-
ences in postoperative outcomes were analyzed using Chi-square test for categorical variables, inde-
pendent sample t-test for continuous variables and Mann-Whitney U test for non-parametric data.
Results: 2926 patients were included. In total, 288 patients received SCRT-delay and 2638 patients un-
derwent CRT. Patients in the SCRT-delay group were older and had more comorbidities. Also, ICU-
admissions and permanent colostomies were more common, as well as pulmonic, cardiologic, infec-
tious and neurologic complications. After PSM, both groups comprised 246 patients with equivalent age,
comorbidities and tumor stage. There were no differences in postoperative complications.
Conclusion: Postoperative complications were not increased in LARC patients undergoing SCRT-delay as
neoadjuvant treatment. Regarding treatment-related complications, SCRT-delay is a safe alternative
neoadjuvant treatment option for frail LARC patients.
© 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.Introduction
In compliance with European guidelines, neoadjuvant treat-
ment for locally advanced rectal cancer (LARC) in the Netherlands08 GA Utrecht, Netherlands.
(S. Hoendervangers).
on for Cancer Surgery, and the Eur
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y, https://doi.org/10.1016/j.ejcomprises neoadjuvant chemoradiation (CRT), followed by surgery
according to total mesorectal excision (TME) principles. Short-
course radiotherapy followed by surgery after a prolonged inter-
val (SCRT-delay) is recommended as an alternative to chemo-
radiation in older patients with comorbidities or frail patients with
a poor performance status, because of their higher risk of treatment
related complications [1].
Postoperative morbidity and mortality are often increased inopean Society of Surgical Oncology. All rights reserved.
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Data on surgical management of rectal cancer in these patients is
scarce and reported postoperative morbidity and mortality vary
widely in the population >65 years old [2e4]. This patient group
might benefit from altered treatment, especially when they are
more susceptible to treatment-related complications [5]. Moreover,
inadequate treatment is associated with poor survival [2]. Unfor-
tunately, the heterogeneity of this group and the lack of data
impede an evidence-based choice of neoadjuvant treatment in this
patient group [6]. With the aging population, there is need for
evidence to justify the choice of the most optimal neoadjuvant
treatment in frail patients with LARC.
Previous trials suggest that SCRT-delay could serve as an
adequate neoadjuvant treatment for intermediate to high risk
rectal cancer [7e9]. Although previous trials showed that an in-
terval <10 days between SCRT and surgery is associated with
anastomotic leakage and postoperative mortality [10,11], the rate of
postoperative complications in the Stockholm III trial was lower
when surgery was delayed for 4e12 weeks after SCRT [12], sug-
gesting that it is better to prolong the interval between SCRT and
surgery. Before adding this regimen to current guidelines, more
data is needed on postoperative outcomes of SCRT-delay in com-
parison to CRT. The aim of this study was to investigate the effect of
SCRT-delay on postoperative outcomes in comparison with CRT, in
both the general and the frail population.
Methods
Study design
This was an observational study with data from the Dutch
ColoRectal Audit (DCRA), a nationwide audit which registers clin-
ical outcomes of all patients undergoing primary colorectal surgery
in the Netherlands. The DCRA is based on evidence-based guide-
lines and is validated on a yearly basis with data from the
Netherlands Cancer Registry (NCR) [13]. Because data could not be
traced back to individual patients, neither informed consent nor
ethical approval was required for this study.
Patient selection
All patients with cT2 rectal cancer who underwent surgery
betweenMay 2014 (after implementation of a newDutch colorectal
cancer guideline) and December 2017, were selected from the DCRA
database. Based on Dutch guidelines, LARCwas defined as cT4, cTany
with mesorectal fascia (MRF) involvement, or cTanyN2. All patients
with LARC were included in the study. Clinical tumor stage was
based on imaging. Patients were excluded in case of metastatic
disease, tumors located outside the rectum, emergency or urgent
surgery. Also, patients who did not receive neoadjuvant treatment,
with a missing start date of neoadjuvant therapy, or patients who
underwent surgery after an interval of less than 6 weeks after the
end of radiotherapy were excluded. Furthermore, patients who
underwent surgery after an initial watch and wait strategy were
excluded from the dataset, since the prolonged interval in this
group could be associated with higher morbidity and a more
difficult surgical resection [14]. Finally, patients who received
intraoperative Hyperthermic Intraperitoneal Chemotherapy
(HIPEC) or Intraoperative Radiation Therapy (IORT) were excluded.
Neoadjuvant therapy
Neoadjuvant treatment entailed either SCRT (25 Gy in fractions
of 5 Gy in 5 days) or CRT (45e50 Gy in fractions of 1.8e2 Gy in 5
weeks and concurrent oral Capecetabine 825e1000 mg/m2 twicePlease cite this article as: Hoendervangers S et al., The effect of ne
chemoradiation on postoperative outcomes in locally advanced rectal ca
study, European Journal of Surgical Oncology, https://doi.org/10.1016/j.ejdaily 5e7 days a week). Interval to surgery was calculated from the
end of neoadjuvant treatment. The interval between the end of
SCRT and surgery was calculated by subtracting 4 days from the
interval when treatment started on Monday or by subtracting 6
days from the interval when treatment started on another day,
accounting for discontinuation of therapy in the weekend. The
same syntax was used for CRT patients, subtracting 32 or 34 days,
respectively.
Data collection
Patient characteristics included gender, age at surgery, BMI (kg/
m2), number and type of comorbidities, and ASA score. Charlson
Comorbidity Index was calculated according to the weighted index
of comorbidity [15]. Tumor characteristics included clinical TNM-
stage, MRF involvement and tumor distance from the anus
(measured at colonoscopy). Treatment characteristics included
type of neoadjuvant treatment (SCRT or CRT), date of surgery,
surgical procedure and approach, intraoperative complications,
conversion, and ostomy creation. The subgroup ‘Minimally invasive
approaches’ included transanal endoscopic microsurgery (TEM),
local excision and transanal minimally invasive local excision
(TAMIS). Hartmann procedure was incorporated in the subgroup
‘(Low) Anterior Resection’. Subtotal colectomy, proctocolectomy
and sigmoid resection were combined in the subgroup ‘other sur-
gical procedures’ because of low prevalence. Intraoperative com-
plications comprised injury of intra-abdominal structures,
complications requiring blood transfusion or other non-specified
complications.
Outcome measures
Follow-up time was 30 days after surgery. The primary outcome
measure was the occurrence of postoperative complications.
Complications were defined according to standards of the DCRA
[13]. Postoperative complications comprised both surgical and non-
surgical complications and were defined as hospital stay of 14
days and/or a complication, re-intervention due to a complication,
and/or death during hospital stay or within 30 days after surgery.
Postoperative surgical complications included anastomotic failure,
abscess, bleeding, ileus, dehiscent fascia, iatrogenic bowel injury,
ureter/urethra injury, or other non-specified complications. Post-
operative non-surgical complications included pulmonary, cardiac,
thrombotic, infectious, neurologic or other non-specified
complications.
Postoperative outcome measures included re-intervention,
prolonged hospital stay, intensive care unit (ICU) stay and re-
admission. Re-intervention involved any laparotomy-, laparo-
scopic- or radiology-assisted treatment for a complication.
Admission to the ICU and length of hospital staywere dichotomized
based on the median length of admission. ICU stay was defined as
admission to the ICU for at least 1 day. Prolonged hospital stay was
defined as admission to the surgical ward for more than 7 days.
Pathological outcomes included pathological tumor and nodal
stage, pathological complete response rate (ypT0N0) and resection
margin.
Missing data
On average, there was 2.3% missing data. Missing values were
classified as random and replaced by multiple imputation. All
observed data, including the outcome, that were applied to the
dataset after imputation were used as predictors [16,17]. The
number of imputations depended on the average percentage rate of
missingness [18,19]. The imputed data were checked withoadjuvant short-course radiotherapy and delayed surgery versus
ncer patients e A propensity score matched nationwide audit-based
so.2020.03.002
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mingled and were free of any trend [17]. Finally, 5 imputed datasets
were produced with 5 iterations.
Propensity score matching
Since frail patients are more likely to receive SCRT-delay or to
experience postoperative complications, and the type of surgery is
a determinant of postoperative complications, the likelihood of
confounding by indication needed to be accounted for. To enable a
comparison in equivalent groups, propensity score matching was
performed [20]. The propensity score was calculated for each pa-
tient using logistic regression with the variables age, Charlson Co-
morbidity Index, cT-stage, and surgical procedure. These covariates
were chosen based on their clinical relevance. Propensity score
matching was performed using ‘nearest-neighbor matching’
without replacement and a 1:1 ratio. The average within-pair dif-
ference in propensity scores was minimized by setting a caliper of
0.25 multiplied by the standard deviation of the logit of the pro-
pensity score [21]. The balance in the matched dataset was
expressed in ‘standardized mean difference’ (SMD), with an
SMD < 0.10 indicating a well-balanced set [22e24].
Statistical analyses
Differences in baseline characteristics and treatment outcomes
were analyzed using Chi-square test for categorical variables and
independent sample t-test for continuous variables. Mann-
Whitney U test was used for non-parametric data. The Bonferroni
correction was applied to account for multiple testing. The level of
significance was set at p < 0.05.
All analyses were performed in IBM SPSS Statistics (version 23 -©
2015 IBM Corporation) and RStudio (Version 1.0.143e © 2009e2016
RStudio, Inc.,‘mice’, ‘tableone’, ‘MatchIt’ and ‘optmatch’ packages).
Results
Patient selection
Between May 2014 and December 2017, 8318 patients with
cT2 rectal cancer were registered in the DCRA database. Patients
without locally advanced tumors (n ¼ 3541), with metastatic dis-
ease (n ¼ 986), with tumors located outside the rectum (n ¼ 257),
who underwent urgent or emergency surgery (n¼ 15), who did not
receive neoadjuvant treatment or if the start date of neoadjuvant
therapy was missing (n ¼ 31), who received chemotherapy only or
chemotherapy combined with short-course radiotherapy (n¼ 102),
who underwent surgery after an interval of less than 6 weeks after
the end of radiotherapy (n ¼ 298) or after an initial watch and wait
strategy (n ¼ 34) and who underwent HIPEC or IORT (n ¼ 128)
(Supplementary Fig. 1) were excluded. Finally, 2926 patients were
included in the analysis. Non-imputed data are provided in
Supplementary Tables 1 and 2
Pre-matching results
Patients in the SCRT-delay group had a higher mean age, had
more comorbidities and a higher ASA score (Table 1). Mean BMI
was higher in the CRTgroup. TheMRFwas less often involved in the
SCRT-delay group and clinical N-stage was higher. There was no
difference in the distance from the anus at colonoscopy. With an
equal interval between neoadjuvant treatment and surgery, pa-
tients in the SCRT-delay group more often underwent abdomi-
noperineal resection (APR) and more often received a permanent
colostomy. In the SCRT-delay group, 63 patients (21.9%) received aPlease cite this article as: Hoendervangers S et al., The effect of ne
chemoradiation on postoperative outcomes in locally advanced rectal ca
study, European Journal of Surgical Oncology, https://doi.org/10.1016/j.ejprimary anastomosis, compared to 1253 patients (47.5%) in the CRT
group. Pulmonic, cardiologic, infectious and neurologic complica-
tions were significantly more common in the SCRT-delay group
(Table 2). When stratified for procedure, there were significant
more complications after APR in the SCRT-delay group; however,
pulmonic, cardiologic, infectious and neurologic complications in
the SCRT-delay group occurred independent of type of surgical
procedure (Supplementary Table 3). There was no difference in the
number of re-interventions. In patients that received a primary
anastomosis, the frequency of re-interventions for anastomotic
leakage was not different after SCRT-delay or CRT (6.3% vs 7.6%,
respectively). Patients in the SCRT-delay group were more often
admitted to the ICU and hospital stay was more often prolonged.
Furthermore, SCRT-delay less often resulted in a pathological
complete response compared to CRT (8.0% vs. 16.1%, Table 1). There
were no differences in surgical radicality after SCRT-delay or CRT
(92.7% vs. 95.2% R0 resections, respectively).
Post-matching results
Baseline characteristics that entered the propensity score model
are presented in Supplementary Table 4. After matching, both
groups comprised 246 patients and characteristics were well-
balanced. Differences in patient, treatment and pathological char-
acteristics between SCRT-delay and CRT in the post-matching
cohort are presented in Table 3. After matching, BMI was higher
in the CRT group. 57 patients in the SCRT-delay group (23.2%)
received a primary anastomosis, compared to 73 patients (29.7%) in
the CRT group. Permanent colostomies were more frequent in the
SCRT-delay group, but this difference was not significant in the
post-matching cohort. There were no differences in pathological
outcomes. Overall, there were no differences in postoperative
(surgical) complications (Table 4). The number of re-interventions
for anastomotic leakage in patients that received a primary anas-
tomosis was not significantly different between groups (5.3% vs.
2.7% after SCRT-delay vs. CRT, respectively). There were no differ-
ences in ICU admission and hospital stay.
Discussion
In this nationwide, propensity score matched studywe found no
difference in the occurrence of surgical complications between
patients who underwent SCRT-delay or CRTas neoadjuvant therapy
for LARC. However, more pulmonic, cardiologic, infectious and
neurologic complications in the pre-matching cohort in the SCRT-
delay group. These differences diminished when patients were
matched on age, gender, comorbidities, tumor characteristics and
distance from the anus.
The pre-matching cohort represents daily clinical practice in the
Netherlands. With the addition of SCRT-delay as regimen for LARC
to the Dutch guidelines in 2014, more elderly patients are offered
neoadjuvant treatment [25]. In our dataset, 642 of 2926 (21.9%)
patients who underwent surgery were aged 75 years. The per-
centage of old and frail patients was higher in the SCRT-delay
group, but these patients were also represented in the CRT group,
which underlines the heterogeneity of the elderly population and
the differences in treatment choice due to lack of evidence-based
data. Previous studies showed various results in incidence of
postoperative morbidity and mortality in the elderly [2e5,26e28].
Taking into account that mortality increases when postoperative
complications occur [5,27] and anastomotic leakage results in
significantly more anorectal and urinary symptoms and higher Low
Anterior Resection Syndrome (LARS) scores [29,30], the lower
prevalence of primary anastomosis in the SCRT-delay group in the
unmatched cohort might be a result of a defensive attitude towardsoadjuvant short-course radiotherapy and delayed surgery versus
ncer patients e A propensity score matched nationwide audit-based
so.2020.03.002
Table 1
Patient, tumor and pathological characteristics in the pre-matching cohort. Data are presented as number (percentage) unless stated otherwise.
SCRT-delay n ¼ 288 CRT n ¼ 2638 p-value
Patient characteristics
Gender 0.021 *
Male 161 (55.9) 1663 (63.0)
Female 127 (44.1) 975 (37.0)
Age (mean years (sd)) 77.89 (8.76) 64.59 (10.25) <0.001 *
BMI (mean kg/m2 (sd)) 25.54 (3.94) 26.27 (4.35) 0.006 *
Comorbidities 249 (86.5) 1765 (66.9) <0.001 *
Charlson Comorbidity Index <0.001 *
0 103 (35.8) 1645 (62.4)
1 85 (29.5) 554 (21.0)
2 48 (16.7) 277 (10.5)
3 31 (10.8) 111 (4.2)
 4 21 (7.3) 51 (1.9)
ASA score <0.001 *
1 20 (6.9) 575 (21.8)
2 157 (54.5) 1686 (63.9)
3 103 (35.8) 363 (13.8)
4 8 (2.8) 14 (0.5)
Tumor characteristics
Distance from anus at colonoscopy (mean cm (sd)) 6.69 (4.69) 6.36 (4.42) 0.224
cT 0.425
2 8 (2.8) 95 (3.6)
3 225 (78.1) 1971 (74.7)
4 55 (19.1) 572 (21.7)
Distance to MRF > 1 mm 58 (20.1) 721 (27.3) 0.003 *
cN <0.001 *
0 77 (26.7) 346 (13.1)
1 80 (27.8) 648 (24.6)
2 129 (44.8) 1637 (62.1)
x 2 (0.7) 7 (0.3)
Treatment characteristics
Interval between end of neoadjuvant treatment and surgery (median weeks [IQR]) 11.00 [9.00, 15.00] 11.00 [10.00, 13.00] 0.472
Surgical approach <0.001 *
Transabdominal open 58 (20.1) 561 (21.3)
Transabdominal scopic 204 (70.8) 1933 (73.3)
TaTME or TAMIS TME 18 (6.2) 134 (5.1)
Minimally invasive 8 (2.8) 10 (0.4)
Surgical procedure <0.001 *
Local excision 8 (2.8) 6 (0.2)
(Low) Anterior Resection 155 (53.8) 1607 (60.9)
Abdominoperineal Resection 124 (43.1) 996 (37.8)
Other 1 (0.3) 29 (1.1)
Conversion 39 (13.5) 341 (12.9) 0.839
Reason conversion 0.658
Extensive tumor growth 8 (2.8) 6 (0.2)
Accessibility 28 (9.7) 216 (8.2)
Intraoperative complication 3 (1.0) 47 (1.8)
Intraoperative complication 0.954
No 275 (95.5) 2506 (95.0)
Bleeding 1 (0.3) 17 (0.6)
Spleen injury 0 (0.0) 1 (0.0)
Bowel injury 3 (1.0) 19 (0.7)
Ureter/urethra injury 4 (1.4) 26 (1.0)
Bladder injury 1 (0.3) 17 (0.6)
Vagina injury 1 (0.3) 12 (0.5)
Other 3 (1.0) 40 (1.5)
Primary anastomosis 64 (22.2) 1257 (47.6) <0.001 *
Ostomy <0.001 *
No 57 (19.8) 521 (19.7)
Diverting ileostomy 27 (9.4) 773 (29.3)
Permanent ileostomy 1 (0.3) 29 (1.1)
Diverting colostomy 7 (2.4) 125 (4.7)
Permanent colostomy 195 (67.7) 1186 (45.0)
Stoma, unknown type 1 (0.3) 4 (0.2)
Pathological characteristics
pT 0.001 *
0 27 (9.4) 512 (19.4)
1 15 (5.2) 157 (6.0)
2 75 (26.0) 623 (23.6)
3 152 (52.8) 1202 (45.6)
4 19 (6.6) 125 (4.7)
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Table 1 (continued )
SCRT-delay n ¼ 288 CRT n ¼ 2638 p-value
x 0 (0.0) 13 (0.5)
Unknown 0 (0.0) 6 (0.2)
pN 0.831
0 185 (64.2) 1776 (67.3)
1 67 (23.3) 571 (21.6)
2 35 (12.2) 282 (10.7)
x 1 (0.3) 7 (0.3)
Unknown 0 (0.0) 2 (0.1)
Pathological complete response, ypT0N0 23 (8.0) 425 (16.1) <0.001 *
Radicality (R0 resection) 267 (92.7) 2512 (95.2) 0.087
Abbreviations: sd ¼ standard deviation, IQR ¼ interquartile range, BMI ¼ Body Mass Index (kg/m2), ASA ¼ American Society of Anesthesiologists, TaTME ¼ Transanal Total
Mesorectal Excision, TAMIS TME ¼ TransAnal Minimal Invasive Surgery - Total Mesorectal Excision, pT ¼ pathological tumor stage, pN ¼ pathological nodal stage.
Table 2
Postoperative outcomes in the pre-matching cohort. Data are presented as number percentage) unless stated otherwise.
SCRT-delay n ¼ 288 CRT n ¼ 2638 p-value
Any postoperative complication < 30 days after surgery 124 (43.1) 987 (37.4) 0.070
Non-surgical complications < 30 days after surgery
Pulmonic 25 (8.7) 102 (3.9) <0.001 *
Cardiologic 18 (6.2) 71 (2.7) 0.002 *
Infectious 32 (11.1) 136 (5.2) <0.001 *
Thrombotic 1 (0.3) 14 (0.5) 1.000
Neurological 12 (4.2) 38 (1.4) 0.002 *
Other 48 (16.7) 360 (13.6) 0.188
Surgical complications < 30 days after surgery 66 (22.9) 653 (24.8) 0.538
Re-intervention 31 (10.8) 317 (12.0) 0.598
Type of re-intervention 0.334
Radiologic 2 (0.7) 35 (1.3)
Surgery, laparoscopic 3 (1.0) 69 (2.6)
Surgery, open 19 (6.6) 138 (5.2)
Other 7 (2.4) 76 (2.9)
Reason re-intervention 0.572
Anastomotic failure a 4 of 64 (6.3) 96 of 1257 (7.6)
Abscess 9 (3.1) 74 (2.8)
Bleeding 1 (0.3) 11 (0.4)
Ileus 2 (0.7) 40 (1.5)
Fascial dehiscence 2 (0.7) 17 (0.6)
Iatrogenic bowel injury 0 (0.0) 5 (0.2)
Ureter/urethra injury 2 (0.7) 5 (0.2)
Other 9 (3.1) 62 (2.4)
 1 day on ICU 98 (34.0) 712 (27.0) 0.014 *
Hospital stay  7 days 145 (50.3) 1076 (40.8) 0.002 *
Readmission < 30 days after surgery 36 (12.5) 384 (14.6) 0.539
Death during or  30 days after surgery 4 (1.4) 23 (0.9) 0.268
Abbreviations: ICU ¼ intensive care unit.
a Data shown for patients that received a primary anastomosis.
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operative complications were seen in this cohort after APR in the
SCRT-delay group. However, the low prevalence indicates that
conclusions should be drawn cautiously. Also, the rate of pulmonic,
cardiologic, infectious and neurologic complications was higher in
this group. However, this was not related to surgical procedure and
can therefore most likely be explained by the frailty of the SCRT-
delay population. The lack of differences in surgical complications
can partly be explained by improved quality of care and better
selection of patients [6,31]. Moreover, frail patients that did not
undergo surgical resection were not included in this study.
In the pre-matching cohort we found a significant lower pCR
rate in the SCRT-delay group (8.0% vs. 16.1%) after a median interval
to surgery of 11 weeks. This is comparable with pCR rates of 4.4%e
25% in literature, with intervals to surgery varying from 4 to 19
weeks [9,32e40]. However, there were some differences in tumor
characteristics between the groups in our dataset. Furthermore, we
cannot relate these outcomes to local recurrence rates or survival.
Three-year OS of 73e78% vs. 65e82.4% and DFS of 53e59% vs.
52e75.1% have been previously described for SCRT-delay and CRT,Please cite this article as: Hoendervangers S et al., The effect of ne
chemoradiation on postoperative outcomes in locally advanced rectal ca
study, European Journal of Surgical Oncology, https://doi.org/10.1016/j.ejrespectively [9,32]. However, these studies included younger, WHO
0e1 patients. Differences in survival are partly determined by dif-
ferences in patient selection for surgical treatment and choices in
management of older patients with colorectal cancer might greatly
affect population-based survival [41]. Also, the majority of these
patients received adjuvant chemotherapy. This is not a part of
routine care in the Netherlands.
The post-matching cohort represents a comparison of SCRT-delay
and CRT in two groups with equivalent age and comorbidities. Here
we did not find a difference in postoperative complications nor in
pathological outcomes between SCRT-delay and CRT. These results
are in line with 2 randomized trials comparing SCRT-
delay ± chemotherapy and CRT [9,32]. Also, in the Stockholm III trial
the frequency of postoperative complications decreased by delaying
surgery with 4e8 weeks after SCRT [8,12]. This indicates that,
considering surgery-related complications and pathological out-
comes,SCRT-delaycouldbeagoodalternativeneoadjuvant treatment
option for LARC patients who are unable to undergo CRT. However,
informationontreatmentcompliance is lacking fromthis study. In the
Stockholm III trial, 7% of patients were hospitalized for radiationoadjuvant short-course radiotherapy and delayed surgery versus
ncer patients e A propensity score matched nationwide audit-based
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Table 3
Differences in patient, treatment and pathological characteristics between SCRT-delay and CRT in the matched cohort. Data are presented as numbers (percentage), unless
stated otherwise.
SCRT-delay CRT p-value
n ¼ 246 n ¼ 246
Patient characteristics
Gender 0.078
Male 142 (57.7) 162 (65.9)
Female 104 (42.3) 84 (34.1)
Age (mean years (sd)) 76.72 (8.86) 75.90 (8.39) 0.294
BMI (mean kg/m2 (sd)) 25.51 (3.96) 26.30 (3.91) 0.027 *
Comorbidities 208 (84.6) 223 (90.7) 0.091
ASA score 0.148
1 20 (8.1) 18 (7.3)
2 132 (53.7) 152 (61.8)
3 87 (35.4) 74 (30.1)
4 7 (2.8) 2 (0.8)
Tumor characteristics
Distance from anus at colonoscopy (mean cm (sd)) 5.91 (4.17) 6.62 (4.54) 0.071
cT 0.681
2 7 (2.8) 9 (3.7)
3 190 (77.2) 182 (74)
4 49 (19.9) 55 (22.4)
Distance to MRF > 1 mm 52 (21.1) 61 (24.8) 0.123
cN 0.047 *
0 61 (24.8) 37 (15)
1 68 (27.6) 69 (28)
2 115 (46.7) 138 (56.1)
x 2 (0.8) 2 (0.8)
Treatment characteristics
Interval between end of neoadjuvant treatment and surgery (median weeks [IQR]) 11.00 [9.00, 15.00] 11.00 [10.00, 13.00] 0.361
Surgical approach 0.660
Transabdominal open 48 (19.5) 54 (22)
Transabdominal scopic 179 (72.8) 175 (71.1)
TaTME or TAMIS TME 17 (6.9) 13 (5.3)
Minimally invasive 2 (0.8) 4 (1.6)
Surgical procedure 0.849
Local excision 2 (0.8) 4 (1.6)
(Low) Anterior Resection 133 (54.1) 128 (52)
Abdominoperineal Resection 110 (44.7) 113 (45.9)
Other 1 (0.4) 1 (0.4)
Conversion 33 (13.4) 33 (13.4) 1.000
Reason conversion 0.469
Extensive tumor growth 5 (2.0) 10 (4.1)
Accessibility 24 (9.8) 21 (8.5)
Intraoperative complication 4 (1.6) 2 (0.8)
Intraoperative complication 0.967
Bleeding 1 (0.4) 1 (0.4)
Spleen injury 0 1 (0.4)
Bowel injury 1 (0.4) 2 (0.8)
Ureter/urethra injury 3 (1.2) 2 (0.8)
Bladder injury 1 (0.4) 1 (0.4)
Vagina injury 1 (0.4) 1 (0.4)
Other 2 (0.8) 1 (0.4)
Primary anastomosis 57 (23.2) 73 (29.7) 0.125
Ostomy 0.054
No 50 (20.3) 34 (13.8)
Diverting ileostomy 25 (10.2) 42 (17.1)
Permanent ileostomy 1 (0.4) 4 (1.6)
Diverting colostomy 7 (2.8) 8 (3.3)
Permanent colostomy 163 (66.3) 158 (64.2)
Pathological characteristics
pT 0.293
0 23 (9.3) 38 (15.4)
1 12 (4.9) 14 (5.7)
2 64 (26) 62 (25.2)
3 131 (53.3) 115 (46.7)
4 16 (6.5) 17 (6.9)
pN 0.478
0 154 (62.6) 168 (68.3)
1 59 (24) 48 (19.5)
2 32 (13) 27 (11)
x 0 1 (0.4)
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Table 3 (continued )
SCRT-delay CRT p-value
n ¼ 246 n ¼ 246
Pathological complete response, ypT0N0 19 (7.7) 31 (12.6) 0.101
Radicality (R0 resection) 226 (91.9) 219 (89) 0.357
Abbreviations: sd ¼ standard deviation, IQR ¼ interquartile range, BMI ¼ Body Mass Index (kg/m2), ASA ¼ American Society of Anesthesiologists, cT ¼ clinical tumor stage,
cN ¼ clinical nodal stage, MRF ¼ mesorectal fascia, TaTME ¼ Transanal Total Mesorectal Excision, TAMIS TME ¼ TransAnal Minimal Invasive Surgery - Total Mesorectal
Excision, pT ¼ pathological tumor stage, pN ¼ pathological nodal stage.
Table 4
Differences in postoperative outcomes between SCRT-delay and CRT in the matched cohort. Data are presented as numbers (percentage), unless stated otherwise.
SCRT-delay CRT p-value
n ¼ 246 n ¼ 246
Any postoperative complication <30 days after surgery 102 (41.5) 93 (37.8) 0.461
Non-surgical complications < 30 days after surgery
Pulmonic 18 (7.3) 10 (4.1) 0.173
Cardiologic 14 (5.7) 11 (4.5) 0.681
Infectious 25 (10.2) 16 (6.5) 0.192
Thrombotic 0 1 (0.4) 1.000
Neurological 0 0 1.000
Other 38 (15.4) 38 (15.4) 1.000
Surgical complications < 30 days after surgery 54 (22) 46 (18.7) 0.433
Re-intervention 22 (8.9) 25 (10.2) 0.759
Type of re-intervention 0.769
Radiologic 0 1 (0.4)
Surgery, laparoscopic 3 (1.2) 2 (0.8)
Surgery, open 13 (5.3) 13 (5.3)
Other 6 (2.4) 9 (3.7)
Reason re-intervention 0.504
Anastomotic failure a 3 of 57 (5.3) 2 of 73 (2.7)
Abscess 7 (2.8) 8 (3.3)
Bleeding 0 0
Ileus 1 (0.4) 5 (2)
Fascial dehiscence 2 (0.8) 1 (0.4)
Iatrogenic bowel injury 0 2 (0.8)
Ureter/urethra injury 1 (0.4) 0
Other 7 (2.8) 6 (2.4)
 1 day on ICU 72 (29.3) 76 (30.9) 0.768
Hospital stay > 7 days 125 (50.8) 106 (43.1) 0.104
Readmission < 30 days after surgery 28 (11.4) 31 (12.6) 0.781
Death during or  30 days after surgery 2 (0.8) 4 (1.6) 0.434
Abbreviations: ICU ¼ intensive care unit.
a Data shown for patients that received a primary anastomosis.
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toxicity are in favor of SCRT (compared to CRT) [1], but more data is
needed. Furthermore, long-term outcomes on local recurrence and
survival is needed.
This is the first observational study that compares complications
after SCRT-delay and CRT in a large population. Since observational
studies cannot determine treatment effects as accurately as ran-
domized trials [22], this propensity score matched study may
provide a useful estimation of the differences between SCRT-delay
and CRT. Nonetheless, the results of this study should be inter-
preted carefully. Confounding bias is frequently seen in observa-
tional studies [42,43]. Patient and disease characteristics may have
influenced the selection of patients for neoadjuvant and surgical
treatment. Most likely, only well-conditioned patients are included
in this database. The biggest pitfall of this study, however, is con-
founding by indication, since the selection of neoadjuvant treat-
ment is confounded by patient factors, which are also related to the
outcome [44,45]. Adjusting for confounding by indication using
propensity score analysis is reliable when data on all factors asso-
ciated with the intervention and the outcome is precise and can be
accounted for [23,44]. However, unadjusted confounding may still
exist if unmeasured factors influenced treatment selection. This
may lead to biased results [22,23,46].Please cite this article as: Hoendervangers S et al., The effect of ne
chemoradiation on postoperative outcomes in locally advanced rectal ca
study, European Journal of Surgical Oncology, https://doi.org/10.1016/j.ejThe aging population, the rising incidence and the improved
prognosis of rectal cancer will increase the need for surgery in the
elderly population in the future [4,26]. Successful treatment of
elderly patients depends on whether it is done safely, allowing
them to preserve good quality of life, and a life-expectancy that is
not reduced by the treatment [2]. Regarding surgery-related com-
plications, SCRT-delay is a good alternative neoadjuvant treatment
option for frail LARC patients. However, information on treatment
compliance and quality of life is needed. Secondly, before the
indication for SCRT-delay can be expanded to intermediate risk
rectal cancer or high risk rectal cancer in the general population,
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